CD274 and neoplasm: This innovative micro-droplet technology allows not only the detection of viable S100-secreting CMCs at the single-cell level, but also the immunostaining of all CMCs before their encapsulation, for instance for the identification of tumor cells that could be targeted by immunotherapy (e.g., PD-L1-positive).